Asthma News - May 1, 2025

Current asthma research, announcements and opportunities, collected and distributed by Michigan Department of Health & Human Services (MDHHS) Asthma Program Staff. Sign up to receive weekly-ish news emails.

Check out the most recent MDHHS asthma social media messages and share them with your networks.

Asthma Empowerment Summit 2025 ~ May 31, 7:30-2:30 PM, Livonia, MI

This free event hosted by the Michigan Medicine Asthma Program will serve as an invaluable resource for those with asthma and healthcare providers, offering insights into asthma management strategies and treatment options. Meals and a small gift bag are included. Don’t miss your chance to attend- register today!

Truth Initiative: 3 myths about mental health and quitting nicotine

At the crossroads of nicotine addiction and mental health are two demographics that are highly affected: teens and young adults. Research shows several connections between nicotine addiction and increased symptoms of anxiety and depression, and while many people misinterpret nicotine as a stress reliever, it may be making their symptoms worse.

Allergy & Asthma Network: Newly Updated! 2025 Respiratory Treatments Poster

The popular Respiratory Treatments poster is updated in time for Asthma and Allergy Awareness Month! The poster includes all available asthma and COPD meds: quick-relief inhalers, long-acting inhalers, inhaled corticosteroids, combo meds and biologics. Free download, also available in Spanish.

Asthma exacerbation (AE) comorbidity index (AECI): Predicting in-hospital adverse outcomes

The high prevalence of comorbidities among patients with AEs is associated with a poorer prognosis. The AECI proves to be a valuable tool to assess comorbidities, enabling clinicians to identify inpatients at higher risk of adverse in-hospital events and to make informed treatment decisions.

Centers for Disease Control & Prevention: Tobacco Product Use Among Adults — United States, 2017–2023

During 2017–2023, the approximate 6.8 million-person decrease in the number of adults who currently exclusively smoke cigarettes was offset by an approximate 7.2 million-person increase in the number who currently exclusively use e-cigarettes.

Dupilumab efficacy in patients with type 2 asthma and early fractional exhaled nitric oxide (FeNO) reductions

Dupilumab sustained efficacy for up to 3 years in patients with and without a minimally important early FeNO reduction. Greater improvements were seen in patients with an early FeNO reduction, but patients without it also showed favorable outcomes during their treatment with dupilumab.